Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LB-LR1109 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on LB-LR1109, a putative anti-LILRB1 monoclonal antibody (Sep 2024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LB-LR1109 | LB LR1109|LBLR1109 | Limited information is currently available on LB-LR1109, a putative anti-LILRB1 monoclonal antibody (Sep 2024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06332755 | Phase I | Atezolizumab + LB-LR1109 LB-LR1109 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC (LB-LR1109) | Recruiting | USA | 0 |